A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.

Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J and 5 more

Show all authors

Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y

Chinese medical journal1 Dec 2009Cited by 5 (Europe PMC)

PMID20137477PepBankPUB-20137477

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, rhPTH increased lumbar BMD more than elcatonin at 3 months (2.38% versus 0.59%).
In plain wordsTeriparatide increased spine bone density more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
2.38%
rhPTH(1-34), 3 months
Lumbar spine BMD increase
0.59%
Elcatonin, 3 months
Source sentences
Summary
rhPTH (1-34) increased lumbar BMD significantly more than did elcatonin at 3 months and 6 months (2.38% vs 0.59%, P < 0.05; 5.51% vs 1.55%, P < 0.01), but there were no significant increases of BMD in these two groups at femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747701
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, rhPTH increased lumbar BMD more than elcatonin at 6 months (5.51% versus 1.55%).
In plain wordsTeriparatide increased spine bone density more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
5.51%
rhPTH(1-34), 6 months
Lumbar spine BMD increase
1.55%
Elcatonin, 6 months
Source sentences
Summary
rhPTH (1-34) increased lumbar BMD significantly more than did elcatonin at 3 months and 6 months (2.38% vs 0.59%, P < 0.05; 5.51% vs 1.55%, P < 0.01), but there were no significant increases of BMD in these two groups at femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747702
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, femoral neck BMD did not significantly increase with rhPTH or elcatonin.
In plain wordsFemoral neck bone density did not significantly increase with teriparatide or elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n = 205
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Source sentences
Summary
rhPTH (1-34) increased lumbar BMD significantly more than did elcatonin at 3 months and 6 months (2.38% vs 0.59%, P < 0.05; 5.51% vs 1.55%, P < 0.01), but there were no significant increases of BMD in these two groups at femoral neck.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747703
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, BSAP increased more with rhPTH than elcatonin at 3 months (36.79% versus 0.31%).
In plain wordsTeriparatide increased the bone marker BSAP more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBSAP at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Serum BSAP increase
36.79%
rhPTH(1-34), 3 months
Serum BSAP increase
0.31%
Elcatonin, 3 months
Source sentences
Summary
There were larger mean increases in bone markers in the rhPTH (1-34) group than in the elcatonin group at 3 months and 6 months (serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine (NTX/Cr) 48.91% vs -5.32%; 68.82% vs -10.86%).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747704
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, BSAP increased more with rhPTH than elcatonin at 6 months (92.42% versus -0.17%).
In plain wordsTeriparatide increased the bone marker BSAP more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBSAP at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Serum BSAP increase
92.42%
rhPTH(1-34), 6 months
Serum BSAP increase
−0.17%
Elcatonin, 6 months
Source sentences
Summary
There were larger mean increases in bone markers in the rhPTH (1-34) group than in the elcatonin group at 3 months and 6 months (serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine (NTX/Cr) 48.91% vs -5.32%; 68.82% vs -10.86%).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747705
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, NTX/Cr increased more with rhPTH than elcatonin at 3 months (48.91% versus -5.32%).
In plain wordsTeriparatide increased NTX/Cr more than elcatonin at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNTX/Cr at 3 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Urinary NTX/Cr increase
48.91%
rhPTH(1-34), 3 months
Urinary NTX/Cr increase
−5.32%
Elcatonin, 3 months
Source sentences
Summary
There were larger mean increases in bone markers in the rhPTH (1-34) group than in the elcatonin group at 3 months and 6 months (serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine (NTX/Cr) 48.91% vs -5.32%; 68.82% vs -10.86%).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747706
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal osteoporosis, NTX/Cr increased more with rhPTH than elcatonin at 6 months (68.82% versus -10.86%).
In plain wordsTeriparatide increased NTX/Cr more than elcatonin at 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNTX/Cr at 6 months
Study
n = 205
Comparator
Elcatonin
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Mean change in urinary NTX/Cr at 6 months
68.82%
rhPTH (1-34) group
Mean change in urinary NTX/Cr at 6 months
−10.86%
elcatonin group
Source sentences
Summary
There were larger mean increases in bone markers in the rhPTH (1-34) group than in the elcatonin group at 3 months and 6 months (serum bone-specific alkaline phosphatase (BSAP) 36.79% vs 0.31%; 92.42% vs -0.17%; urinary N-telopeptide/creatinine (NTX/Cr) 48.91% vs -5.32%; 68.82% vs -10.86%).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747707
08HumanRandomized controlled trialSafety outcome
In postmenopausal osteoporosis, adverse event proportions did not differ significantly between rhPTH and elcatonin (67.0% versus 59.0%).
In plain wordsAdverse event rates did not differ significantly between teriparatide and elcatonin.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAny adverse events
Study
n = 205
Comparator
Elcatonin
Outcome group
Adverse events · Whole body
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Proportion with any adverse event
67%
rhPTH (1-34) group (first value of the pair)
Proportion with any adverse event
59%
elcatonin group (second value of the pair)
Source sentences
Summary
Both treatments were well tolerated and there were no significant differences detected between the two groups in the proportion of any adverse events and any serious adverse events (67.0% vs 59.0%; 0 vs 0).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747708
09HumanRandomized controlled trialSafety outcome
In postmenopausal osteoporosis, neither rhPTH nor elcatonin recipients had serious adverse events.
In plain wordsNeither teriparatide nor elcatonin recipients had serious adverse events.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerious adverse events
Study
n = 205
Comparator
Elcatonin
Outcome group
Adverse events · Whole body
Studied dose
20 microg daily · 6 monthsAs given in this study (human).
Measurements
Number of serious adverse events
0 events
rhPTH (1-34) group (first value of the pair)
Number of serious adverse events
0 events
elcatonin group (second value of the pair)
Source sentences
Summary
Both treatments were well tolerated and there were no significant differences detected between the two groups in the proportion of any adverse events and any serious adverse events (67.0% vs 59.0%; 0 vs 0).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred and five women with osteoporosis were enrolled in a 6-month, multicenter, randomized, controlled study.
Summary · context
They were randomized to receive either rhPTH (1-34) 20 microg (200 U) daily or elcatonin 20 U weekly.
Report a problemFND-2013747709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.